AstraZenecaIt is failure of advanced trial for Wainua It was never expected to have a major financial impact on the company.
Most analysts estimate that the trial’s failure only wiped 2% to 4% of their valuation models. Yet shares lost about double that in a single session, suggesting the market reaction reflects more than just the loss of a drug intended to treat a rare heart condition.
This disconnect has diverted attention from Wainua itself to something harder to measure: Is the valuation premium that investors have long assigned to one of Europe’s most storied drug pipelines justified?
For years, AstraZeneca has enjoyed the highest valuations among major European pharmaceutical companies, based on the assumption that management consistently successfully conducts late-stage clinical trials in oncology, rare diseases and specialty drugs, and replenishes its portfolio with new blockbuster drugs.
Under CEO Pascal Soriot’s 14-year reign, AstraZeneca developed a reputation as a pharmaceutical powerhouse that rarely releases negative trial results.
Wainua itself was not expected to become one of AstraZeneca’s most important products. Rather, the surprise lay in the failure of a program that many investors saw as having a strong chance of success.
Analysts mostly say the disappointment doesn’t hurt AstraZeneca’s performance. long-term growth storybut this may have raised the bar for proving it.
The problem goes beyond the additional revenue Wainua allegedly added to AstraZeneca’s top line, as it damages the company’s credibility, Jefferies analysts wrote in a note to clients on Thursday.
“It was supposed to be a slam dunk, which made the outright failure surprising.”
Bigger than medicineThe financial impact of Wainua’s failure as a treatment for ATTR cardiomyopathy, a rare and life-threatening heart disease, appears relatively modest.
Citi estimates the impact on net present value to be approximately 3%. Jefferies estimates it at around 2%, and Leerink Partners’ price target reduction implied a similarly limited impact. Bank of America described the sales impact as “mid-single digits,” while Morningstar said the drop in Wainua’s sales estimates did not materially change its valuation.
These estimates contrast with the market’s reaction, with shares falling 6.2% during Thursday’s session, marking the stock’s worst day in more than two years, and losing another 3% on Friday.
An AstraZeneca spokesperson declined to comment further on the share price reaction.
Read more pharmaceutical newsRather than simply removing some of Wainua’s sales from their models, investors could reevaluate their confidence in AstraZeneca’s broader pipeline and execution.
Dan Coatsworth, head of markets at AJ Bell, noted that AstraZeneca has had far more successes than failures recently, creating high expectations for success.
“AstraZeneca has bold plans to reach $80 billion in revenue by 2030, and investors will now question whether that goal is credible,” Coatsworth said in emailed comments.
Jefferies said the failed trial does not threaten management’s ambition for 2030, while Citi continues to expect the company can exceed that target.
Leerink noted that after speaking to management, the withdrawal of Wainua due to ATTR cardiomyopathy reduces the margin above the company-provided consensus from approximately $82.7 billion to approximately $80.8 billion, reflecting $1.9 billion in Wainua revenue in 2030.
Morningstar left its fair value estimate unchanged, saying the setback “does not change our view of its late-stage drug development capabilities,” while noting that AstraZeneca’s oncology franchise, rare diseases business and broader pipeline remain intact.
Goldman Sachs and Bank of America stressed that investors had not seriously considered the possibility of the trial failing, given the favorable precedent of Alnylam the rival drug Amvuttra which works in the same way.
A diminishing margin of error?The study failure also comes at an important time for AstraZeneca.
Several of the company’s biggest pipeline catalysts – including the AVANZAR trial for lung cancer, SERENA-4 for breast cancer and cliramitug also for ATTR cardiomyopathy – are expected to release data in the coming months, meaning investor attention is now focused on fewer high-profile reads.
Stock chart iconStock chart icon
AstraZeneca shares listed in London for the last 12 months.
“All eyes are on AVANZAR,” Jefferies wrote, describing it as the next major catalyst that could determine sentiment. The reading is expected in July or August.
Leerink suggested that this setback puts even more emphasis on the remaining “binary events” expected later this year.
Most analysts continue to recommend buying the stock. Citi reiterated AstraZeneca as its top European pharmaceutical pick, Bank of America reiterated its buy rating and Jefferies argued investors should “buy the dip.”